-
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner October 10th, 2019, Bangkok, Thailand — Today, Red Herring announced its Top 100 Asia award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Asia enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1000 privately financed companies each year in the Asia. Since 1996, ...Oct. 15. 2019 -
EOFLOW Chosen as Company of the Year
EOFLOW made it to the 'Top 10 Diabetes Care Solutions Providers - 2019' list and was chosen as the Company of the Year by Medtech Outlook magazine (see the attachment for a reprint). One can read more about it at: https://diabetes-care.medicaltechoutlook.com/vendors/top-diabetes-care-companies.htmlOct. 07. 2019 -
Menarini Diagnostics & EOFlow sign a long term business agreement
EOFlow Co., Ltd. and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of Innovative Insulin Patch Pump Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd. “We are very pleased and excited to work with A. Menarini Diagno...Sep. 17. 2019 -
EOFLOW Receives Breakthrough Device Designation from FDA
EOFlow Receives FDA Breakthrough Device Designation on its Integrated Wearable Automated Insulin Delivery System SAN JOSE, USA and SEOUL, South Korea, March 14, 2019 EOFLOW CO., Ltd., an emerging medical device company with offices in Seoul, South Korea and San Jose, California, announced today that its closed loop Automated Insulin Delivery /Artificial Pancreas Device (AID/AP), the EOPancreas System, has received Breakthrough Device Designation by the U.S. Food and Drug Administration. The EOPancreas System is designed to pr...Mar. 14. 2019 -
EOFLOW covered in a major newspaper article
Maeil Business News Korea (www.mk.co.kr), one of the most widely read economics newspapers in Korea, discusses EOFLOW's wearable insulin pump in its article covering the new medical trend of focusing on improved user experience. To read the Korean article, click the link below: http://news.mk.co.kr/newsRead.php?year=2018&no=343754May. 31. 2018 -
EOFLOW investment story on TV
MTN (Money Today Network), one of the most popular financial TV networks in Korea, runs a story on how Huons Global, EOFLOW's exclusive distribution partner in Korea, invests in EOFLOW in its in-depth story that covers the recent trend of established Korean bio and pharma companies identifying and investing in promising startup biotech companies. The video clip and text of the clip can be found in the link here, in Korean only: http://news.mtn.co.kr/newscenter/news_viewer.mtn?gidx=2018052111062224948 &n...May. 28. 2018 -
EOFLOW closes two back-to-back rounds of funding
EOFLOW announces the closing of its Series-C and C+ rounds of funding. Through this unusual back-to-back funding rounds with two different valuations (with the C+ being higher than the C-round that closed unannounced a month earlier), the company has raised a total of 14Billion KRW (about $14M) from four investors, of which two are existing shareholders of EOFLOW. With the latest rounds of funding, combined with the recent award from JDRF (Juvenile Diabetes Research Foundation) and some fresh gove...May. 04. 2018 -
President Malave interviews a major newspaper in Korea
Luis Malave, the president of EOFLOW, visited Korea recently and had an interview with one of the major Korean newspapers. Here is the link to the article, in Korean only: http://news.naver.com/main/read.nhn?mode=LSD&mid=sec&oid=015&aid=0003925789&sid1=001Apr. 26. 2018 -
EOFLOW awarded a government grant to develop automatic insulin delivery system
EOFLOW is awarded a government R&D grant for developing a wearable disposable automatic insulin delivery system that functionally integrates a continuous glucose sensor and a wearable insulin pump to provide highly automated blood glucose control service with little or no user attention. "This award, together with the recent award from JDRF (Juvenile Diabetes Research Foundation) and the licensing of the highly proven closed-loop algorithm from Typezero, will bring us one step closer to a successful launch of ...Apr. 16. 2018 -
EOFLOW in a newspaper article
The Investor, a startup-centric English news service run by a highly respected Korean English newspaper, Korea Herald, recently covered an article on EOFLOW: http://www.theinvestor.co.kr/view.php?ud=20180405000593Apr. 13. 2018 -
Dr. Ian Welsford joins EOFLOW as a new Chief Compliance Officer
Dr. Ian Welsford, a long-time industry insider who has seen the emergence of the smart insulin patch pump industry, has joined EOFLOW as the new Chief Compliance Officer. Dr. Welsford brings to EOFlow over 25 years of experience in Quality Assurance, Regulatory and Clinical Affairs working primarily in the medical device industry with an emphasis on electromechanical systems including insulin pumps (external and implantable), closed loop blood glucose control (a.k.a. artificial pancreas) systems, in vitro diagnostic syst...Apr. 09. 2018 -
TypeZero and EOFlow to Develop Closed Loop System Featuring AP Technology and Patch Insulin Pump
CHARLOTTESVILLE, Va. and SEOUL, South Korea – Digital health company TypeZero Technologies, Inc. and medical device manufacturer EOFlow Co., LTD today announced the companies have completed a license agreement to implement TypeZero’s closed loop technology alongside EOFlow’s patch insulin pump. The non-exclusive agreement allows for development of a closed loop product that can be commercialized throughout Asia. EOFlow’s EOPatch system features a disposable patch insulin pump that is among the smallest and lightes...Feb. 14. 2018 -
EOFLOW gets media coverage around the globe
With the recent joint announcement between JDRF (Juvenile Diabetes Research Fund) and EOFLOW, the company and its wearable insulin patch pump product, EOPatch, are getting some attention. Check out the links below: From MobiHealthNews: 'JDRF backs EOPatch, a tiny, wearable insulin pump' http://www.mobihealthnews.com/content/jdrf-backs-eopatch-tiny-wearable-insulin-pump From MD+DI newsletter (Qmed): 'How Two Tiny Insulin Devices Won JDRF Support' https://www.mddionline.com/how-two-tiny-insulin-devices-won-jdrf-support Fr...Feb. 06. 2018 -
EOFLOW covered in a major newspaper article
Maeil Business News Korea (www.mk.co.kr), one of the most widely read economics newspapers in Korea, runs an article on EOFLOW and its wearable automated insulin infusion system (AKA artificial pancreas) development support by JDRF (Juvenile Diabetes Research Fund). To read the Korean article, click the link below: http://news.mk.co.kr/newsRead.php?year=2018&no=63532Jan. 29. 2018
Healthcare Innovation Park #H2102 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
